Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Multi-Center, Randomized, Double Blind Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of Lucanthone Administered as an Adjunct to Radiation and Temozolomide for Primary Therapy of Glioblastoma Multiforme

Next Previous
Trial Profile

An International, Multi-Center, Randomized, Double Blind Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of Lucanthone Administered as an Adjunct to Radiation and Temozolomide for Primary Therapy of Glioblastoma Multiforme

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lucanthone (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Spectrum Pharmaceuticals

Most Recent Events

  • 03 Apr 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
  • 14 Feb 2013 Planned number of patients changed from 140 to 210 as reported by ClinicalTrials.gov.
  • 07 Aug 2012 New source identified and integrated (Clinical Trials Registry - India),

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top